Preeclampsia Risk Stratification Assay
Early prediction and risk stratification of preeclampsia
Development/ValidationActive
Key Facts
Indication
Early prediction and risk stratification of preeclampsia
Phase
Development/Validation
Status
Active
Company
About Savran Technologies
Savran Technologies is a private, pre-revenue diagnostics company pioneering a novel, non-invasive approach to predicting preeclampsia. Its technology platform isolates ultra-rare cells from urine to detect upstream biomarkers as early as 10 weeks of gestation, far earlier than current methods. The company's lead program received FDA Breakthrough Device Designation in January 2026, validating its potential to address a major unmet need in maternal-fetal health. SavranTech is positioned to tap into a large global market by enabling timely, prophylactic intervention to prevent adverse outcomes.
View full company profile